Azelis stock valuation debate sharpens after five-year slump

Azelis stock traded at 11.77 euros on Lang & Schwarz at 09:31 CET on Monday, November 2, 2026. The latest market focus is a valuation debate rather than a new operating announcement. A Yahoo Finance analysis by Simply Wall St published on October 31 argued that the specialty distributor's cash generation may support a higher valuation, while also highlighting risks around margins and leverage.

Cash Flow Supports The Bull Case

The analysis said Azelis generated 380.5 million euros of free cash flow over the latest twelve months. Its discounted-cash-flow model assumed that cash generation would continue to grow through 2030, with the pace easing as the business matures. On that basis, the model indicated an intrinsic value substantially above the 11.71-euro share price cited in the analysis.

The argument rests on Azelis' role as a value-added distributor of specialty chemicals and food ingredients. The group says it serves more than 65,000 customers in 64 countries and works with more than 2,800 principals. Its offering combines distribution with formulation support, application laboratories and technical guidance, factors that can influence pricing power and cash conversion.

Margins And Leverage Keep Risks High

The same analysis presented a more cautious counterpoint. Azelis' adjusted EBITA fell 12.7 percent in 2025, net profit declined 37.6 percent and the gross margin narrowed by 91 basis points to 23.6 percent. Adjusted EBITA margin also fell 170 basis points to 10.0 percent. These figures leave the recovery dependent on improving profitability rather than revenue growth alone.

Cost savings are part of that recovery effort. The analysis cited Azelis' 20 million-euro structural cost-saving plan and said 11 million euros had contributed in the first half of 2026. The company has also placed emphasis on digital tools, artificial intelligence and its Customers First Choice and Future Fit programs. Those initiatives could support earnings quality, but execution and debt reduction remain important conditions for a sustained re-rating.

Recent Growth Changes The Narrative

Azelis' third-quarter performance provided a more constructive operating backdrop. The company reported 8.5 percent year-on-year revenue growth and 8.2 percent organic growth, while organic adjusted EBITA growth reached 14.3 percent. Industrial Chemicals was the stronger division, whereas pressure in parts of Life Sciences continued to complicate the broader margin picture.

That combination explains the split valuation view: improving organic momentum and cash generation support the upside case, while leverage and the recovery of margins limit the certainty of the model's assumptions. Investors can follow the real-time quote of Azelis stock.

Belgian equities can be followed through current market reports.

More news and analyses on Azelis stock are available in the company topic.